1. KD. Tripathi. Hypolipidaemic Drugs and Plasma Expanders. Essentials of medical pharmacology. Seventh edition. 2013. Page – 641.
2. Thomas P. Bersot. Drug therapy for Hypercholesterolemia and Dyslipidemia. Goodman & Gilman’s: The Pharmacological basics of Therapeutics. 12th Edition. New York McGraw Hill Medical 2011. Page – 903-904.
3. Gerald G. Briggs and Roger K. Freeman. E. A reference guide to fetal and neonatal risk: Drugs in Pregnancy and Lactation. Tenth Edition. 2015. Page – 1516-1517.
4. Merck Sharp & Dohme Corp. A Study of SCH 58235 (Ezetimibe) When Added to Ongoing Therapy with a Statin in Participants with Primary Hypercholesterolemia, Known Coronary Heart Disease, or Multiple Cardiovascular Risk Factors (P02173). NIH U.S. National Library of Medicine ClinicalTrials.gov. [Revised on June 2019] [Accessed 25th November 2020] https://clinicaltrials.gov/ct2/show/NCT03882905
5. Luis C. L. Correia. Ezetimibe: Clinical and Scientific Meaning of the IMPROVE-IT Study. NCBI; PMC US National Library of Medicine, National Institute of Health. March 2016. [Accessed 25th November 2020] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4811280/
6. Daniel Hammersley and Mark Signy. Ezetimibe: an update on its clinical usefulness in specific patient groups. NCBI; PMC US National Library of Medicine, National Institute of Health. November 2016. [Accessed 25th November 2020] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5298356/
7. S.C. Zentiva, S.A. Electronic Medicines Compendium (EMC); [Revised on September 2020] [Accessed 25th November 2020] https://www.medicines.org.uk/emc/files/pil.9109.pdf
8. Merck/Schering-Plough Pharmaceuticals. U.S. Food & Drug Administration. January 2006. [Accessed 25th November 2020] https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021445s014lbl.pdf